{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:07:30Z","timestamp":1795036050576,"version":"4.10.2"},"reference-count":24,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The Cure Sickle Cell Initiative (CureSCi), created by the National Heart, Lung, and Blood Institute, has developed data standards to increase interoperability and meta-analysis of studies specifically investigating gene therapy for sickle cell disease (SCD). The aims of the CureSCi Common Data Elements (CDE) initiative are to facilitate the development of safe, effective, and accessible gene therapies. Five working groups (WGs) comprising people living with SCD, stakeholders, clinicians, and researchers reviewed current definitions used for SCD clinical studies, including those from the American Society of Hematology, US Food and Drug Administration, PhenX catalog of consensus measures for phenotypes and exposures, and others. The WGs met over 1.5 years to develop a comprehensive list of defined data points and variables recommended for any gene therapy clinical trial that incorporated feedback from a 60-day public review period. The SCD CDEs are publicly available on the CureSCi (curesickle.org\/datatools-overview) and the National Institutes of Health (NIH) Repository (cde.nlm.nih.gov\/home) websites. In addition to data elements, there are 42 instrument recommendations, including those from the Patient-Reported Outcomes Measurement Information System and NIH Toolbox, and 49 template case report forms for various stages of a study (eg, demographic, disease history, treatment, and outcome). CureSCi data element recommendations build upon current consensus data elements and facilitate the start-up of multicenter clinical research efforts. This standardized set of clinical research recommendations will increase the ability to compare outcomes across studies, increase data quality, and help educate new clinical investigators in the field of SCD gene therapy research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019400","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:58:21Z","timestamp":1775505501000},"page":"3960-3965","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Cure Sickle Cell Initiative recommendations on common data elements for sickle cell disease gene therapy trials"],"prefix":"10.1182","volume":"10","author":[{"given":"Sophie","family":"Lanzkron","sequence":"first","affiliation":[{"name":"1Division of Hematology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7745-7223","authenticated-orcid":false,"given":"Victoria H.","family":"Coleman-Cowger","sequence":"additional","affiliation":[{"name":"2Emmes, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4961-8103","authenticated-orcid":false,"given":"Alexis A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"3Division of Hematology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7511-916X","authenticated-orcid":false,"given":"C. Patrick","family":"Carroll","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci","family":"Clemons","sequence":"additional","affiliation":[{"name":"2Emmes, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-1604","authenticated-orcid":false,"given":"Michael","family":"DeBaun","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7002-8891","authenticated-orcid":false,"given":"Julie","family":"Kanter","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-2108","authenticated-orcid":false,"given":"Punam","family":"Malik","sequence":"additional","affiliation":[{"name":"6Hematology and Gene Therapy Program, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Manwani","sequence":"additional","affiliation":[{"name":"7Department of Hematology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis John","family":"Pierciey","sequence":"additional","affiliation":[{"name":"8Tessera Therapeutics, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6515-4559","authenticated-orcid":false,"given":"Mark C.","family":"Walters","sequence":"additional","affiliation":[{"name":"9Division of Hematology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherita","family":"Alai","sequence":"additional","affiliation":[{"name":"2Emmes, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"3","key":"2026060911324286400_bib14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1740774512438980","article-title":"National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods","volume":"9","author":"Grinnon","year":"2012","journal-title":"Clin Trials"},{"key":"2026060911324286400_bib23","unstructured":"NINDS CDE References\n          . NINDS Common Data Elements. \/References."},{"key":"2026060911324286400_bib18","unstructured":"Association of Public Health Laboratories\n          . Hemoglobinopathies: Current Practices for Screening, Confirmation, and Follow-up. Accessed 13 April 2026. https:\/\/www.aphl.org\/aboutAPHL\/publications\/Documents\/NBS_HemoglobinopathyTesting_122015.pdf."},{"issue":"15","key":"2026060911324286400_bib2","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/blood-2012-04-424184","article-title":"Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis","volume":"120","author":"Bartolucci","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2026060911324286400_bib12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000342232","article-title":"Measurement of red cell lifespan and aging","volume":"39","author":"Franco","year":"2012","journal-title":"Transfus Med Hemother"},{"issue":"suppl_1","key":"2026060911324286400_bib17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2019-126727","article-title":"Fetal hemoglobin measurement per red blood cell provides biological and clinical protective thresholds","volume":"134","author":"Hebert","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2026060911324286400_bib27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.25443","article-title":"Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients","volume":"94","author":"Rab","year":"2019","journal-title":"Am J Hematol"},{"issue":"21","key":"2026060911324286400_bib33","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood.V124.21.2704.2704","article-title":"Pan-selectin antagonist rivipansel (GMI-1070) reduces soluble E-selectin levels while improving clinical outcomes in SCD vaso-occlusive crisis","volume":"124","author":"Wun","year":"2014","journal-title":"Blood"},{"key":"2026060911324286400_bib15","volume-title":"Guidance for Industry: Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)","year":"2020"},{"key":"2026060911324286400_bib16","volume-title":"Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products","year":"2011"},{"issue":"3","key":"2026060911324286400_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"2026060911324286400_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2026060911324286400_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB -206 study","volume":"98","author":"Kanter","year":"2023","journal-title":"Am J Hematol"},{"issue":"8","key":"2026060911324286400_bib8","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults","volume":"4","author":"DeBaun","year":"2020","journal-title":"Blood Adv"},{"issue":"23","key":"2026060911324286400_bib10","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/bloodadvances.2019000882","article-title":"End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain","volume":"3","author":"Farrell","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2026060911324286400_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12955-014-0125-0","article-title":"Patient reports of health outcome for adults living with sickle cell disease: development and testing of the ASCQ-Me item banks","volume":"12","author":"Keller","year":"2014","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"2026060911324286400_bib29","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/AJP.0000000000000054","article-title":"Adult sickle cell quality-of-life measurement information system (ASCQ-Me): conceptual model based on review of the literature and formative research","volume":"30","author":"Treadwell","year":"2014","journal-title":"Clin J Pain"},{"issue":"8","key":"2026060911324286400_bib24","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/pbc.24491","article-title":"PedsQLTM sickle cell disease module: feasibility, reliability, and validity: PedsQLTM sickle cell disease module","volume":"60","author":"Panepinto","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2026060911324286400_bib25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11136-011-9941-4","article-title":"Development of the PedsQLTM sickle cell disease module items: qualitative methods","volume":"21","author":"Panepinto","year":"2012","journal-title":"Qual Life Res"},{"issue":"1","key":"2026060911324286400_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12955-017-0661-5","article-title":"Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS\u00ae to ASCQ-MeSM","volume":"15","author":"Keller","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"2026060911324286400_bib26","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/jpepsy\/jsz031","article-title":"Cognitive function in sickle cell disease across domains, cerebral infarct status, and the lifespan: a meta-analysis","volume":"44","author":"Prussien","year":"2019","journal-title":"J Pediatr Psychol"},{"issue":"18","key":"2026060911324286400_bib30","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1001\/jama.2010.562","article-title":"Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia","volume":"303","author":"Vichinsky","year":"2010","journal-title":"JAMA"},{"issue":"1","key":"2026060911324286400_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/pbc.22222","article-title":"Vaso-occlusive painful events in sickle cell disease: impact on child well-being","volume":"54","author":"Brandow","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2026060911324286400_bib5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/pbc.25931","article-title":"Responsiveness of PROMIS\u00ae pediatric measures to hospitalizations for sickle pain and subsequent recovery","volume":"63","author":"Dampier","year":"2016","journal-title":"Pediatr Blood Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3960\/2523610\/blooda_adv-2025-019400-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3960\/2523610\/blooda_adv-2025-019400-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:32:52Z","timestamp":1781019172000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/3960\/567594\/Cure-Sickle-Cell-Initiative-recommendations-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019400","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,5,28]]}}}